There's nothing like starting the new year on a high note with news of a record venture financing. Cambridge, Mass.-based Moderna Therapeutics Inc. said it closed a whopping $450 million financing that will fuel and expand its messenger RNA (mRNA) therapeutics platform across a number of therapeutic indications.